Show/Hide Menu
Hide/Show Apps
Logout
Türkçe
Türkçe
Search
Search
Login
Login
OpenMETU
OpenMETU
About
About
Open Science Policy
Open Science Policy
Open Access Guideline
Open Access Guideline
Postgraduate Thesis Guideline
Postgraduate Thesis Guideline
Communities & Collections
Communities & Collections
Help
Help
Frequently Asked Questions
Frequently Asked Questions
Guides
Guides
Thesis submission
Thesis submission
MS without thesis term project submission
MS without thesis term project submission
Publication submission with DOI
Publication submission with DOI
Publication submission
Publication submission
Supporting Information
Supporting Information
General Information
General Information
Copyright, Embargo and License
Copyright, Embargo and License
Contact us
Contact us
Biotinylated Diaryl Isoxazole Derivatives with Enhanced Janus Kinase 1 Inhibitory, Antiproliferative, and Apoptotic Activities in Cancer Cells
Date
2026-06-30
Author
Ergüven, Melike
Çatalak Yılmaz, Hazal Beril
LENGERLİ, DENİZ
Acar, Rana
Bagheralmoosavi, Servin
Carus Şahin, Yağmur Öykü
Gürçay, Mehmet
ÇALIŞKAN, BURCU
Banerjee, Sreeparna
Yesiloz, Gurkan
Konu, Ozlen
BANOĞLU, ERDEN
Cizmecioglu, Onur
Metadata
Show full item record
This work is licensed under a
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
.
Item Usage Stats
28
views
0
downloads
Cite This
Isoxazole derivatives have emerged as promising scaffolds in anticancer drug discovery, yet their therapeutic potential remains to be fully harnessed. Here, we report on the synthesis and biological evaluation of two novel biotin-conjugated isoxazole derivatives (C160 and C161) related to the parent compound EB38. Across a panel of liver, prostate, and breast cancer cell lines, both derivatives exhibited significantly enhanced antiproliferative and pro-apoptotic activities compared to EB38, with consistently lower IC50 values in 2D cultures and superior efficacy in 3D spheroid models. Mechanistic studies revealed that C160 and C161 robustly inhibit phosphorylation of JAK1 and STAT1, thereby suppressing JAK/STAT signaling and inducing apoptotic marker cleavage (PARP, Caspase-3, Caspase-7). Direct target engagement was further validated by CETSA and DARTS assays, which demonstrated thermal and proteolytic stabilization of endogenous JAK1 in the presence of C160. Molecular docking and HADDOCK simulations supported JAK1 as a direct cellular target, with binding affinities comparable to the clinically approved inhibitor Ruxolitinib. Importantly, zebrafish embryotoxicity assays confirmed that these derivatives do not elicit general cytotoxicity, even at doses substantially exceeding those effective in vitro. Collectively, our findings establish biotinylated isoxazole derivatives as potent JAK1-targeting anticancer agents with strong antiproliferative and pro-apoptotic activity, supporting their further development as promising candidates for targeted cancer therapy.
URI
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=105043489260&origin=inward
https://hdl.handle.net/11511/119900
Journal
ACS Omega
DOI
https://doi.org/10.1021/acsomega.5c08996
Collections
Department of Biology, Article
Citation Formats
IEEE
ACM
APA
CHICAGO
MLA
BibTeX
M. Ergüven et al., “Biotinylated Diaryl Isoxazole Derivatives with Enhanced Janus Kinase 1 Inhibitory, Antiproliferative, and Apoptotic Activities in Cancer Cells,”
ACS Omega
, vol. 11, no. 25, pp. 36501–36519, 2026, Accessed: 00, 2026. [Online]. Available: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=105043489260&origin=inward.